This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AbbVie-Cerevel deal focused on antipsychotic drug hit with second request from US FTC

By Ben Brody ( February 16, 2024, 22:56 GMT | Insight) -- AbbVie’s proposed acquisition of Cerevel Therapeutics, which is focused on Cerevel's investigational treatment for schizophrenia and Alzheimer’s disease psychosis, received a second request from the US Federal Trade Commission. AbbVie already sells a drug to treat schizophrenia and has other treatments in the pipeline aimed at Alzheimer’s disease.AbbVie’s proposed acquisition of Cerevel Therapeutics, which is focused on Cerevel’s investigational treatment for schizophrenia and Alzheimer’s disease psychosis, received a second request from the US Federal Trade Commission....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login